Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

Matthias Dominikus Hofer

doi:10.1111/fcp.12410

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

Matthias Dominikus Hofer^*

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Original language	English (US)
Number of pages	1
Journal	Fundamental and Clinical Pharmacology
Volume	32
Issue number	5
DOIs	https://doi.org/10.1111/fcp.12410
State	Published - Oct 1 2018

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/fcp.12410

Cite this

@article{fd94f06489234120b45d6b2bbe893fce,

title = "Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal",

author = "Hofer, {Matthias Dominikus}",

year = "2018",

month = oct,

day = "1",

doi = "10.1111/fcp.12410",

language = "English (US)",

volume = "32",

journal = "Fundamental and Clinical Pharmacology",

issn = "0767-3981",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

AU - Hofer, Matthias Dominikus

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85053187473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053187473&partnerID=8YFLogxK

U2 - 10.1111/fcp.12410

DO - 10.1111/fcp.12410

M3 - Editorial

C2 - 30209857

AN - SCOPUS:85053187473

VL - 32

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 5

ER -

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this